Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Illinois for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Illinois only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Illinois (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Daniel Frank (NPI 1437194610)

Field	Value
Entity Type	Individual
Organization	Daniel Frank
Address	430 Warrenville Rd
City	Lisle
State	IL
ZIP	60532
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 19, 2006

Payer Source	Total Paid
Medicare	$3.5M
Medicaid	$0

Key Findings

DANIEL FRANK is a Hematology & Oncology Physician in Lisle, IL with an NPI enumerated on 2006-06-19 (~20 years ago). The provider's available payer data shows Total Medicare revenue of $3.5M and no Medicaid billing on file, indicating an effectively single-payer (Medicare) footprint in the available claims dataset.

Revenue is highly concentrated in a small set of high-cost drug/injection codes: J9271 accounts for $1.1M (33.4% of Medicare revenue), J9144 accounts for $752.4K (22.0%), and J0129 accounts for $334.1K (9.8%); together the top three codes account for 65.2% of this provider's total Medicare revenue. This concentration indicates that a majority of Medicare dollars for this provider flow through a handful of infusion and injectable therapies.

The code mix is consistent with an infusion-centered hematology/oncology practice that delivers high-cost monoclonal antibody and supportive biologic therapies in-office or in-clinic. Leading procedure/drug codes include J9271 (pembrolizumab), J9144 (daratumumab with hyaluronidase), Q5111 (pegfilgrastim-cbqv biosimilar) and J0897 (denosumab), alongside chemotherapy administration codes such as 96413 and 96401, which together point to routine administration of oncology therapeutics plus supportive care.

Payer mix is effectively single-payer: the dataset shows Total Medicare revenue of $3.5M and explicitly notes "none below" for Medicaid, so there is no recorded Medicaid billing to analyze. For analysts, this means competitive and utilization benchmarking should focus on Medicare-only dynamics and national rank comparisons rather than state Medicaid activity.

National ranking details show the provider is a meaningful participant on several top drug lines but not uniformly dominant across all codes: J9271 ranks #187 of 1841 (90th percentile) and is described as a typical, unremarkable volume profile in the data, while J9144 ranks #48 of 615 (92th percentile) with a similar characterization; by contrast J0129 ranks #494 of 1221 (59th percentile). These ranks suggest above-average activity on a subset of oncology infusions but more typical volumes on others.

Several codes are flagged as statistical highs in the provided descriptors and merit attention for competitive positioning: J0897 (ranked in the 95th percentile) and Q5111 (rank #8 of 123, 94th percentile) are noted as "notably above typical national volume," 99214 and 96413 are each flagged in the mid-90s percentile as "notably above typical national volume," and 99204 is listed as an "extreme outlier, far above typical national volume." These labels indicate specific service lines and visit types where this provider is unusually active compared with peers.

Although drug and infusion codes dominate revenue, evaluation-and-management visits are present and concentrated in higher-complexity office visits: 99214 (764 claims, $75.6K, 2.2% of Medicare revenue) and 99213 (724 claims, $46.3K, 1.4% of Medicare revenue) appear among top codes. This pattern implies clinical throughput oriented around infusion encounters with E/M billed as complementary visit management rather than as the primary revenue driver.

The provider’s revenue mix includes several biosimilars and agents sensitive to market shifts (for example Q5111 pegfilgrastim-cbqv biosimilar and Q5119 rituximab-pvvr biosimilar alongside branded agents like pembrolizumab and daratumumab), which exposes the practice to reimbursement and utilization changes tied to biosimilar adoption and oncology drug pricing. Analysts should consider this exposure when evaluating future revenue stability and competitive dynamics for this practice.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

76 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	26,600	$40	$1.1M
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	19,800	$40	$752.4K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	9,830	$30	$334.1K
J0897	Injection, denosumab, 1 mg	15,900	$20	$286.2K
J3380	Injection, vedolizumab, intravenous, 1 mg	10,200	$20	$153K
Q5111	Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg	1,360	$110	$147.8K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	4,400	$30	$114.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	760	$100	$75.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	670	$110	$71.4K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	28,100	$1	$56.2K

Showing 1–10 of 76

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 76 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Illinois Distribution

Daniel Frank — 11 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Illinois

Full comparison — all codes billed, vs. state median

76 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	9	110	11,600	$40	$564.2K
J9144	3	50	7,740	$40	$341.8K
J0129	10	50	6,480	$30	$232.4K
J3380	14	30	8,700	$20	$183.8K
J0897	19	410	2,520	$20	$90.8K
J1745	15	60	2,170	$30	$85.1K
Q5111	2	10	430	$110	$66.4K
Q5119	16	40	1,970	$20	$50.6K
J0881	10	70	11,600	$1	$38.2K
J9217	28	160	140	$130	$21.1K

Showing 1–10 of 76

Related Providers

Other providers that share a Tax Identification Number (TIN) with Daniel Frank, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Columbus Radiology Corp	OH	Diagnostic Radiology Physician	$0	$49.9M
Cathryn Goldberg	IL	Hematology (Pathology) Physician	$179.8K	$3.1M
Shantan Reddy	IL	Ophthalmology Physician	$1.2M	$768.5K
Refat Baridi	IL	Hematology & Oncology Physician	$1.7M	$27.6K
Courtney Burland	IL	Physician Assistant	$1.4M	$0
Anand Shah	IL	Therapeutic Radiology Physician	$1.3M	$0
Kimberly Mercurio	IL	Physical Medicine & Rehabilitation Physician	$1M	$2.6K
Katherine Baker	IL	Radiation Oncology Physician	$998K	$0
Umang Patel	IL	Internal Medicine Physician	$417.1K	$575.6K
Nasir Shahab	IL	Hematology & Oncology Physician	$911.7K	$2.5K

Nearby Providers

Other providers in the same ZIP code as Daniel Frank, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Lisle-woodridge Fire Protection District	IL	Ambulance	$535.2K	$7.2M
National Clinical Labs	IL	Clinical Medical Laboratory	$10.6K	$6.2M
Dayone Pact	IL	Case Management Agency	$0	$3.7M
Bruce Linder	IL	Diagnostic Radiology Physician	$82.8K	$611.8K
Lisansha Zahirsha	IL	Diagnostic Radiology Physician	$665.6K	$3.3K
Saadia Yunus	IL	Hematology & Oncology Physician	$441K	$0
Brian Myre	IL	Hematology & Oncology Physician	$226.5K	$32.9K
Steven Baughman	IL	Urology Physician	$174.5K	$17.3K
Thomas Shin	IL	Vascular & Interventional Radiology Physician	$174.8K	$1.7K
Insight Medical Imaging, LLC	IL	Diagnostic Radiology Physician	$147.3K	$0

Daniel Frank — Billing Profile & Reimbursement Data

Sign up for Daniel Frank — Billing Profile & Reimbursement Data policy alerts

Daniel Frank — Billing Profile & Reimbursement Data

Sign up for Daniel Frank — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References